Rita F. Redberg

Jun 13, 2024 | jamanetwork.com | Allison Kratka |Rita F. Redberg |Robert W. Yeh |Richard A Shlofmitz

Paclitaxel-Coated Balloon vs Uncoated Balloon for Coronary In-Stent Restenosis Robert W. Yeh, MD, MSc; Richard Shlofmitz, MD; Jeffrey Moses, MD; William Bachinsky, MD; Suhail Dohad, MD; Steven Rudick, MD; Robert Stoler, MD; Brian K. Jefferson, MD; William Nicholson, MD; John Altman, MD; Cinthia Bateman, MD; Amar Krishnaswamy, MD; J. Aaron Grantham, MD; Frank J. Zidar, MD; Steven P. Marso, MD; Jennifer A. Tremmel, MD, MS; Cindy Grines, MD; Mustafa I. Ahmed, MD; Azeem Latib, MD; Behnam Tehrani, MD; J.

Jun 11, 2024 | statnews.com | Sanket S Dhruva |Rita F. Redberg

Multi-cancer early detection tests (MCEDs), sometimes called liquid biopsy tests, are a new method of detecting cancer early. While the concept is promising, these untested tests currently pose significant problems. MCEDs look for circulating DNA or cells from cancers. The goal is to detect cancer in its earliest stages in people without any signs or symptoms of the disease.

Jun 10, 2024 | jamanetwork.com | Jessica N. Holtzman |Rita F. Redberg

The safety and effectiveness of high-risk medical devices, such as transcatheter valves, neuromuscular stimulators, and orthopedic implants, warrant rigorous review. For more than 4 decades, the US Food and Drug Administration (FDA) has played the central role of evaluating the effectiveness of novel tests, drugs, and medical devices. The FDA’s purpose is to protect the public from unnecessary harm.

May 16, 2024 | onlinelibrary.wiley.com | Renee Y. Hsia |Rita F. Redberg |Yu-Chu Shen

INTRODUCTION American health care is not immune to the popular cultural concept that “more is better.” Studies have shown that some health care services have led to overdiagnosis and overtreatment, resulting in wasteful spending1-3 and potential harm.4-7 In cardiac care, for example, many notable advances have improved the overall expansion of services, but prior literature has found that these services tend to be unequally distributed across communities.8, 9 Herein we explored the impact of...

Aug 28, 2023 | jamanetwork.com | Sanket S Dhruva |Rebecca Smith-Bindman |Rita F. Redberg

The Need for Randomized Clinical Trials Demonstrating Reduction in All-Cause Mortality With Blood Tests for Cancer Screening In recent years, blood tests that look for circulating tumor DNA and biomarkers (termed liquid biopsies) have been developed. As Carr and Welch describe in this issue of JAMA Internal Medicine,1 these tests are being explored for diagnosis of suspected cancer, cancer surveillance after treatment, response to therapy, and chemotherapeutic selection.